NAPISTAR 1-02

A multicenter, Phase Ib/II study to evaluate the safety, tolerability, pharmacokinetics and preliminary clinical activity of TUB-040, in combination with standard ovarian cancer drugs in patients with high-grade epithelial serous or endometroid epithelial ovarian cancer. (NAPISTAR 1-02)

Open

Trial drug

TUB-040

Grade

High grade

Prior lines

1, 2

Histology

Serous, Endometrioid

Platin

Platinum sensitive

Phase

I/II

Treatment

The treatment option in this study is TUB-040.
TUB-040 is given intravenously every 3 weeks, combined with carboplatin (max. 6 cycles) and bevacizumab.

Treatment duration

The treatment can continue until disease progression, unacceptable toxicities or until you decide to stop.

Contact

To be able to give you the best information and care we do not give medical advice via mail. We kindly ask you to make an appointment via lgog@uzleuven.be.